Eukaryotic translation initiation factor 4A2 (EIF4A2) is a gene that encodes a protein that functions as an ATP-dependent RNA helicase that plays a role in cap recognition and is required for mRNA binding to the ribosome. Fusions, missense mutations, nonsense mutations, silent mutations, frameshift deletions, and in-frame deletions are observed in cancers such as breast cancer, endometrial cancer, and skin cancer.
EIF4A2 is altered in 0.85% of all cancers with squamous cell lung carcinoma, lung adenocarcinoma, breast invasive ductal carcinoma, high grade ovarian serous adenocarcinoma, and colon adenocarcinoma having the greatest prevalence of alterations .
The most common alterations in EIF4A2 are EIF4A2 Amplification (0.48%), EIF4A2 Loss (0.03%), EIF4A2 M1? (0.03%), EIF4A2 E25Q (0.01%), and EIF4A2 K382N (0.01%) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.